Literature DB >> 35464289

Pancreatectomy with concomitant portal vein resection in the current neoadjuvant era.

Benedetto Ielpo1, Fernando Burdio1, Ana Martinez1, Patricia Sanchez-Velazquez1.   

Abstract

Entities:  

Year:  2022        PMID： 35464289      PMCID： PMC9023828          DOI： 10.21037/hbsn-21-547

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  14 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.

Authors:  Michele Reni; Gianpaolo Balzano; Silvia Zanon; Alessandro Zerbi; Lorenza Rimassa; Renato Castoldi; Domenico Pinelli; Stefania Mosconi; Claudio Doglioni; Marta Chiaravalli; Chiara Pircher; Paolo Giorgio Arcidiacono; Valter Torri; Paola Maggiora; Domenica Ceraulo; Massimo Falconi; Luca Gianni
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-04-04

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

Authors:  Eva Versteijne; Mustafa Suker; Karin Groothuis; Janine M Akkermans-Vogelaar; Marc G Besselink; Bert A Bonsing; Jeroen Buijsen; Olivier R Busch; Geert-Jan M Creemers; Ronald M van Dam; Ferry A L M Eskens; Sebastiaan Festen; Jan Willem B de Groot; Bas Groot Koerkamp; Ignace H de Hingh; Marjolein Y V Homs; Jeanin E van Hooft; Emile D Kerver; Saskia A C Luelmo; Karen J Neelis; Joost Nuyttens; Gabriel M R M Paardekooper; Gijs A Patijn; Maurice J C van der Sangen; Judith de Vos-Geelen; Johanna W Wilmink; Aeilko H Zwinderman; Cornelis J Punt; Casper H van Eijck; Geertjan van Tienhoven
Journal:  J Clin Oncol       Date:  2020-02-27       Impact factor: 44.544

5.  Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

Authors:  Jin-Young Jang; Youngmin Han; Hongeun Lee; Sun-Whe Kim; Wooil Kwon; Kyung-Hun Lee; Do-Youn Oh; Eui Kyu Chie; Jeong Min Lee; Jin Seok Heo; Joon Oh Park; Do Hoon Lim; Seong Hyun Kim; Sang Jae Park; Woo Jin Lee; Young Hwan Koh; Joon Seong Park; Dong Sup Yoon; Ik Jae Lee; Seong Ho Choi
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

6.  Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.

Authors:  B Ielpo; H Duran; E Diaz; I Fabra; R Caruso; V Ferri; L Malavé; M Hidalgo; R Alvarez; C Plaza; Y Quijano; E Vicente
Journal:  Eur J Surg Oncol       Date:  2016-01-29       Impact factor: 4.424

7.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

8.  Surgical Outcomes of Pancreatectomy with Resection of the Portal Vein and/or Superior Mesenteric Vein and Jejunal Vein for Pancreatic Head Cancer: A Multicenter Study.

Authors:  Yuichi Nagakawa; Jin-Young Jang; Manabu Kawai; Song Cheol Kim; Yosuke Inoue; Yasuhiro Yabushita; Jin Seok Heo; Masayuki Honda; Teiichi Sugiura; Shingo Kagawa; Aoi Hayasaki; Wooil Kwon; Kenichiro Uemura; Ho-Seong Han; Motokazu Sugimoto; Yasuhisa Ando; Masafumi Nakamura; Keita Wada; Yusuke Kumamoto; Hiroaki Osakae; Akihiko Tsuchida; Yoo-Seok Yoon; Joon Seong Park; Hiroki Yamaue; Itaru Endo
Journal:  Ann Surg       Date:  2021-12-14       Impact factor: 12.969

9.  Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.

Authors:  M Y V Homs; G van Tienhoven; M G Besselink; J W Wilmink; Q P Janssen; J L van Dam; B A Bonsing; H Bos; K P Bosscha; P P L O Coene; C H J van Eijck; I H J T de Hingh; T M Karsten; M B van der Kolk; G A Patijn; M S L Liem; H C van Santvoort; O J L Loosveld; J de Vos-Geelen; B M Zonderhuis; B Groot Koerkamp
Journal:  BMC Cancer       Date:  2021-03-23       Impact factor: 4.430

Review 10.  Paradigm shift for defining the resectability of pancreatic cancer.

Authors:  Mee Joo Kang; Sun-Whe Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.